Dawnrays Pharmaceutical Holdings Ltd. announced that Ms. Huang Dongmei resigned as the Chief Executive Officer with effect from 1 March 2015; and (ii) Ms. Li Kei Ling was appointed as the Chief Executive Officer with effect from 1 March 2015. Ms. Li is also an executive director and the chairman of the Board of the company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 HKD | +1.68% | -1.63% | +15.24% |
26/03 | Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 | CI |
25/03 | Dawnrays' 2023 Profit Falls 9% on Lower Revenue | MT |
1st Jan change | Capi. | |
---|---|---|
+15.24% | 229M | |
+37.74% | 723B | |
+32.22% | 598B | |
-2.07% | 364B | |
+20.25% | 331B | |
+2.99% | 288B | |
+16.60% | 244B | |
+9.77% | 210B | |
-5.15% | 208B | |
+7.43% | 169B |
- Stock Market
- Equities
- 2348 Stock
- News Dawnrays Pharmaceutical (Holdings) Limited
- Dawnrays Pharmaceutical Holdings Ltd. Announces Executive Changes, Effective March 31, 2015